Levofolic (Levoleucovorin Disodium)

Levoleucovorin is a reduced folate that bypasses the dihydrofolate reductase step, directly entering the intracellular reduced folate pool. This restores nucleotide synthesis and DNA repair capacity, protecting normal cells from antifolate‑induced damage and, in some regimens, stabilizing the active complex of 5‑fluorouracil.

The dose of Levofolic is individualized by the prescribing clinician based on the specific chemotherapy protocol, patient renal and hepatic function, and the amount of methotrexate or 5‑fluorouracil administered. No fixed regimen can be stated; the prescriber sets the appropriate amount.

Safety data for Levofolic in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To order Levofolic, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Levofolic (levoleucovorin) is a reduced folate that provides more rapid intracellular folate replenishment than folic acid, making it the preferred rescue agent for high‑dose methotrexate. Compared with calcium folinate, it has similar efficacy but is supplied in a sterile injectable form suitable for precise dosing in oncology settings.

Levofolic should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and keep it in the original packaging until use to maintain stability.

Levofolic is administered intravenously by a qualified healthcare professional. It is typically given as an infusion over several minutes, following the timing guidelines of the associated chemotherapy regimen, and may be diluted in compatible IV fluids as instructed by the prescriber.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal failure, and significant hepatic dysfunction. Prompt recognition of these events and immediate medical intervention are essential to mitigate harm.

Levofolic should be avoided in patients with known hypersensitivity to levoleucovorin or any component of the formulation, and in those with severe renal or hepatic impairment where the risk may outweigh benefit. Clinicians must evaluate each case individually.